Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

NCT06868732 | Recruiting Phase 1

• 1 other identifier: JSKN016-102
• Study Type: interventional
• Target: 288
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.

Conditions

Advanced Non-small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

• ORR assessed by the investigator per RECIST v1.1

  Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

  Up to 24months

• Safety reflected by AE

  An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

  Up to 24months

Secondary Outcomes (8)

• DOR assessed by the investigator per RECIST v1.1

  Up to 24months

• DCR assessed by the investigator per RECIST v1.1

  Up to 24months

• TTR assessed by the investigator per RECIST v1.1

  Up to 24months

• PFS assessed by investigator per RECIST v1.1

  Up to 24months

• OS

  Up to 24months

Study Arms (8)

Cohort -1A-a

EXPERIMENTAL

Receive JSKN016 in combination with carboplatin, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Carboplatin

Cohort -1A-b

EXPERIMENTAL

Receive JSKN016 in combination with furmonertinib mesilate tablets, administered at the dosage specified in the protocol.

Drug: JSKN016; Drug: Furmonertinib Mesylate

Cohort -1B

EXPERIMENTAL

Receive JSKN016 in combination with ivonescimab, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Ivonescimab

Cohort -2

EXPERIMENTAL

Receive JSKN016 in combination with docetaxel, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Docetaxel

Cohort -3A

EXPERIMENTAL

Receive JSKN016 in combination with tislelizumab，with or without carboplatin, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Carboplatin; Drug: Tislelizumab

Cohort -3B

EXPERIMENTAL

Receive JSKN016 in combination with ivonescimab，with or without carboplatin, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Carboplatin; Drug: Ivonescimab

Cohort -4

EXPERIMENTAL

Receive JSKN016 in combination with pembrolizumab, administered intravenously at the dosage specified in the protocol.

Drug: JSKN016; Drug: Pembrolizumab

Cohort -5

EXPERIMENTAL

Receive JSKN016 in combination with furmonertinib mesilate tablets, administered at the dosage specified in the protocol.

Drug: JSKN016; Drug: Furmonertinib Mesylate

Interventions

JSKN016 DRUG

Administered intravenously according to protocol.

Cohort -1A-a; Cohort -1A-b; Cohort -1B; Cohort -2; Cohort -3A; Cohort -3B; Cohort -4; Cohort -5

Carboplatin DRUG

AUC 5, Q3W, administered intravenously according to protocol.

Also known as: Carboplatin Injection

Cohort -1A-a; Cohort -3A; Cohort -3B

Furmonertinib Mesylate DRUG

160mg（cohort1A-b）or 80mg（cohort 5）, qd, administered according to protocol.

Also known as: Furmonertinib Mesylate Tablets

Cohort -1A-b; Cohort -5

Ivonescimab DRUG

20mg/kg, Q3W, administered intravenously according to protocol.

Also known as: Ivonescimab Injection

Cohort -1B; Cohort -3B

Docetaxel DRUG

60mg/m\^2, Q3W, administered intravenously according to protocol.

Also known as: Docetaxel injection

Cohort -2

Tislelizumab DRUG

200mg, Q3W, administered intravenously according to protocol.

Also known as: Tislelizumab Injection

Cohort -3A

Pembrolizumab DRUG

200mg, Q3W, administered intravenously according to protocol.

Also known as: Pembrolizumab Injection

Cohort -4

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily participate and sign the informed consent form.
• Age ≥ 18 years old, ≤ 75 years old, male or female.
• Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
• Expected survival ≥ 3 months.
• Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not suitable for radical surgery and/or radical radiotherapy.
• At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
• Recently archived or fresh tumor tissue samples are available.
• Have good organ function.
• Have no current birth plans and agree to contraception during the trial.

You may not qualify if:

• Presence of any small cell carcinoma component in histopathology.
• Subjects with other malignant tumors within 5 years prior to enrollment, and other tumors have been cured through local therapy, such as cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-primary invasive bladder cancer, and prostate/cervical/breast cancer in situ.
• Presence of brainstem, meningeal metastases, spinal cord metastases or compression, leptomeningeal metastases, or history of carcinomatous meningitis; Presence of active brain metastases.
• During the screening period, imaging shows that the tumor invades, compresses, or occurs in the surrounding important organs (such as the heart and pericardium, trachea, esophagus, superior vena cava, etc.) or there is a risk of esophageal tracheal fistula or esophageal pleural fistula.
• Adequate washout of previous therapy before the first dose.
• Gastrointestinal abnormalities with obvious clinical manifestations.
• Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
• Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
• Prior treatment with topoisomerase I inhibitors (e.g., irinotecan, topotecan), antibody-drug conjugates containing topoisomerase I inhibitors (e.g., DS-8201, HER3-DXd, DS-1062), or targeting TROP2 or HER3.
• Previous treatment with docetaxel.
• Have an uncontrolled infection, a history of immunodeficiency, a positive human immunodeficiency virus (HIV) test, or a history of AIDS.
• Previous history of allogeneic bone marrow or organ transplantation.
• Known allergy to any component of the study drug, and previous history of severe allergic reaction to other antibody drugs.
• Pregnant and/or lactating females.
• Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risk and/or uncertainty in survival evaluation, such as tumor leukemia response , cachexia manifestations, etc.

Sponsors & Collaborators

• Jiangsu Alphamab Biopharmaceuticals Co., Ltd: lead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Interventions

Carboplatin; aflutinib; Docetaxel; tislelizumab; pembrolizumab

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes

Study Officials

• Li Zhang

  Sun Yat-sen University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Li Zhang

CONTACT

13902282893; zhangli@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 5, 2025
• First Posted: March 11, 2025
• Study Start: April 2, 2025
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): December 30, 2028
• Last Updated: March 30, 2026

Record last verified: 2025-03

Locations

CN (1)